Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 4,423

Document Document Title
WO/2012/126570A1
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...  
WO/2012/124696A1
[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result...  
WO/2012/120195A1
The invention relates to pyridazinone and pyridone com- pounds having formula (I) or (I'), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1 / R4 and X and X3 are as defined in the claims. The invention...  
WO/2012/120398A1
The invention provides a compound of the formula (I): wherein A, R1, R2 and R3 are as defined herein, or a pharmaceutically acceptable salt thereof. Such compounds are small molecule TRPM8 blockers and therefore useful in the propylaxis ...  
WO/2012/119045A2
Hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, compositions comprising hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, and methods for u...  
WO/2012/097682A1
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compoun...  
WO/2012/091156A1
The present invention relates to a pyridazinone compound of the formula (I): wherein R1 represents hydrogen, a C1-6 alkyl group, and the like, R2 represents halogen, a cyano group, a nitro group, a C1-6 alkoxy group, and the like, G repr...  
WO/2012/085001A1
The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general...  
WO/2012/082857A1
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...  
WO/2012/082853A1
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In an...  
WO/2012/072033A1
Provided are substituted 2,3-phthalazinone compounds, their isomers, salts, solvates, prodrugs, their preparation and the use for the preparation of medicaments for inhibiting the activity of poly (adenosine diphosphate-ribose) polymeras...  
WO/2012/062412A1
Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being a sulpho-group-containing dichloro-diazine selected from compo...  
WO/2012/050041A1
The present invention provides a pest control agent, an acaricide, or a bactericide that contains, as the active ingredient thereof, at least one type of compound selected from aryloxyurea compounds represented by formula (V) (wherein R1...  
WO/2012/048258A2
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.  
WO/2012/038942A1
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonar...  
WO/2012/037132A1
JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating dise...  
WO/2012/037258A1
The present invention relates to processes for preparing enantiomerically pure cyclopropyl amine derivatives and salts thereof; the chiral intermediates such as the chiral salts are useful for the preparation of such chiral compounds and...  
WO/2012/031383A1
Compounds of general formula (I) and pharmaceutically acceptable salts thereof are disclosed, in which R1, R2, R3, R4, R5 and Ar are defined as in the description.  
WO/2012/033225A1
The present invention relates to a novel method for producing a pyridazinone compound and an intermediate thereof as shown in the following scheme: wherein the symbols are as defined in the specification.  
WO/2012/029672A1
The present invention relates to amine derivatives each represented by chemical formula (I) (wherein Ar represents a phenyl group or the like; R1 represents a hydrogen atom or the like; R2 represents a C1-6 alkylcarbonyl group or the lik...  
WO/2012/028629A1
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, f...  
WO/2012/025450A1
New phenylamidines are described, having general formula (I) and their use for the control of phytopathogenic fungi.  
WO/2012/020742A1
Disclosed is a novel compound that acts as an antagonist for P2X3 and/or P2X2/3 receptors. Also disclosed is a pharmaceutical composition that acts as an antagonist for P2X3 and/or P2X2/3 receptors, said composition containing: a compoun...  
WO/2012/014221A1
Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-r...  
WO/2012/013728A1
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...  
WO/2012/014963A1
[Problem] To provide a compound which can act relying on an agonistic activity on cannabinoid receptor type 2 and is therefore useful as a novel and excellent prophylactic and/or therapeutic agent for diseases associated with cannabinoid...  
WO/2012/011081A1
The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a -CH- group; X1 represents a nitrogen atom or a -CH=CH- group; X2 represents an ox...  
WO/2012/004743A1
The invention relates to sulfonamide derivatives, to their use i n medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new ...  
WO/2012/003748A1
Disclosed are a kind of N-oxo-aryloxyphenoxycarboxylic acid amide compounds, preparation method and application thereof. The said N-oxo-aryloxyphenoxycarboxylic acid amide compounds are shown by formula (I), in which R1 is H or C1-C3 alk...  
WO/2012/003189A1
The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.  
WO/2011/154677A1
The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.  
WO/2011/145669A1
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...  
WO/2011/133444A1
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.  
WO/2011/130661A1
Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4...  
WO/2011/118672A1
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...  
WO/2011/107295A1
The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly it was discovered that form I and form II have differing immunological effects. This ad...  
WO/2011/103536A1
The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such...  
WO/2011/097553A1
The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 a...  
WO/2011/095461A1
The present invention relates to novel pyridazine derivatives of formula (I) wherein R1 is methyl or ethyl; R2 is H or chloro; R3 is fluoro or chloro; R4 is fluoro or methoxy; and R5 is chloro or methoxy or an agrochemically usable salt ...  
WO/2011/097649A2
The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including i...  
WO/2011/094953A1
A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.  
WO/2011/076708A1
The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compound...  
WO/2011/066168A1
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z1, R1, p, R3, and R4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders usin...  
WO/2011/051692A1
The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which ma...  
WO/2011/051282A1
The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxyp...  
WO/2011/048523A1
The present invention relates to a novel manufacturing process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially rennin inhibitors such as Aliskiren. The invention describes a preparation of...  
WO/2011/046954A1
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...  
WO/2011/040445A1
The disclosed method for producing a 3-substituted-oxy-4-pyridazinol derivative represented by general formula I is characterized by reacting a compound represented by general formula III and a compound represented by general formula IV ...  
WO/2011/038572A1
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, partic...  
WO/2011/035878A1
The invention relates to phenyl-substituted pyridazinones of formula (I) for use as herbicides and insecticides. In said formula (I) A, B, G, X, Y and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups su...  

Matches 551 - 600 out of 4,423